 RespireRx Pharmaceuticals OTCQB:RSPI Inc said Chief Scientific Officer and Interim CEO Arnold Lippa was an invited speaker at the 2022 GRI Virtual Conference last month, where he discussed the potential use of AMPAkines for the treatment of certain disorders. Lippa described the work that EndeavourRx, the companys business unit focused on neuromodulators, has done to develop a novel class of low-impact AMPAkines that have shown positive results in human studies of target engagement, ADHD, cognition and respiration, the company said. 